CLICK HERE to learn more about Kineta's reverse merger with NASDAQ listed Yumanity Therapeutics (YMTX) announcement
Kineta Inc.
  • about
    • company
    • team
    • board
    • SAB
  • platform
  • pipeline
    • KVA12.1
    • CD27
    • KCP506
    • LHF535
  • partnering
  • investors
  • news
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean
logo

Martin Cheever, 21

Slide Scientific Advisory Board
Martin (Mac) Cheever, MD Dr. Cheever is a Member of Fred Hutchinson Cancer Research Center (FHCRC), a Professor of Medicine and is currently the Principal Investigator and Director for the NCI-funded Cancer Immunotherapy Trials Network (CITN). Through the network, researchers across the continent design and conduct novel, early phase trials of immunotherapy drugs. The goal of these trials is to provide proof of concept that helps advance the most promising new treatment regimens for patients by harnessing the power of the immune system. In his own research outside the CITN, Dr. Cheever has identified principles of T-cell therapy, discovered new targets for cancer therapies, and developed cancer vaccines.

In 2019, Dr. Cheever received the first-ever Distinguished Service Award from the Society for the Immunotherapy of Cancer (SITC). Dr Cheever received his medical degree from the University of Michigan and was cofounder of Corixa Inc, a Seattle biotech company that was founded to develop cancer vaccines.

About This Sidebar

  • To edit this sidebar, go to admin backend's Appearance -> Widgets and place widgets into the BlogSidebar Widget Area

 

 

 

 

 

 

 

join our email list

 

 

 

Kineta is a trademark of Kineta, Inc. ©2021 Kineta, Inc. Legal

Back to Top
English
English
Korean